Samsung’s venture investment arm is participating in a strategic collaboration and investment deal with Exo, a California-based medical imaging startup, as part of a broader initiative to co-develop next-generation ultrasound technologies. The agreement was announced by Exo in a press release dated May 27, 2025.

As part of this collaboration, Samsung Medison, the medical device affiliate of Samsung specializing in diagnostic ultrasound systems, has made a strategic equity investment in Exo.

The goal of the partnership is to accelerate the development of compact, high-performance ultrasound platforms that integrate silicon-based architectures and embedded imaging technologies.

Exo confirmed that Dr. Omar Ishrak has joined its board as Chair of Strategy.

Ishrak is the chairman of Qubit Health Capital and formerly served as Chairman and CEO of Medtronic, as well as CEO of GE Healthcare Systems.

According to Dr. Kyu Tae Yoo, CEO of Samsung Medison, “Our collaboration with Exo marks a significant step toward advancing transformation in ultrasound imaging. We are committed to delivering innovation that improves diagnostic capabilities and enhances the clinical experience for patients and practitioners alike”.

Exo was founded in 2015 and is known for its development of handheld ultrasound devices that connect to smartphones.

These devices allow healthcare professionals to perform scans such as lung exams and echocardiograms and manage exam results through a single app.

To date, Exo has raised over $320 million from a range of investors including RA Capital Management, BlackRock, Intel, Sony, Sands Capital, and Avidity Partners.

The company last raised $220 million in a Series C round in 2021.

Bloomberg previously reported that Exo was raising a new funding round of up to $100 million, led by Sands Capital, Bold Capital, and Qubit Health Capital, with Samsung Ventures in discussions to participate.

The new partnership and board appointment are part of Exo’s broader effort to scale innovation in ultrasound imaging and expand global accessibility.

Representatives from Exo, Samsung, Sands Capital, Bold Capital, and Qubit Health have not immediately commented beyond the official announcements.

PHOTO: EXO.INC

This article was created with AI assistance.